HIGHLIGHTS
- who: Dandan Jiang from the Oncotelic, Inc, United States Taipei Medical University, Taiwan have published the paper: Canagliflozin, characterized as a HDAC6 inhibitor, inhibits gastric cancer metastasis, in the Journal: (JOURNAL)
- what: The authors took advantage of FDAapproved drug library and indicated that canagliflozin effectively inhibits the enzymatic activity of HDAC6 and shows an excellent affinity with HDAC6.
- how: Data were analyzed using GraphPad Prism 8.0 (USA). t-test or one-way analysis of variance (ANOVA) was used for the statistical significance evaluation. As gastric cancer is one of the leading causes . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.